Sales

282.8

187.2

518.2

315.2

357.6

295.3

701.7

598.2

Royalty and commission income*

0.9

1.8

4.4

5.0

2.3

2.3

3.8

4.3

Total revenues

283.7

189.0

522.6

320.2

359.9

297.6

705.5

602.6

Gross margin

204.2

87.8

366.9

143.5

189.3

131.6

379.5

278.0

Marketing and selling expenses*

–8.4

–6.5

–15.1

–12.9

–89.4

–75.3

–170.9

–151.1

Royalty and commission expenses*

–1.9

0.1

–4.3

–0.2

–1.8

–2.0

–4.6

–4.4

Administration expenses

–4.8

–4.4

–8.9

–8.9

–17.4

–16.1

–33.1

–32.2

Other operating expenses and income

–14.5

–2.1

–27.6

–10.7

–19.3

–7.3

–39.3

–20.3

Research and development

–22.7

–22.2

–46.5

–44.4

–13.8

–12.3

–28.1

–26.3

Operating result

151.1

51.8

262.9

64.4

47.2

17.9

102.1

42.4

Exceptional items

–

–

–

–

–

–

–

1.2

Earnings before interest and tax (EBIT)

151.1

51.8

262.9

64.4

47.2

17.9

102.1

43.6

Net operating assets**

–

–

941.6

837.4

–

–

1,230.6

1,120.0

Segment liabilities**

–

–

–82.6

–78.6

–

–

–175.6

–151.6

Capital spending on property, plant and equipment

13.0

13.5

19.5

28.4

15.3

15.7

25.8

35.3

Investments in intangible assets

0.3

1.2

0.6

2.7

2.0

2.1

3.0

4.9

Depreciation

–16.3

–14.7

–32.3

–29.3

–18.8

–17.3

–37.9

–34.8

Impairment losses

–7.4

–

–16.4

–

–

–0.2

–

–0.2

Net cash flows from operating activities

138.9

73.7

249.3

115.4

73.7

67.8

108.9

82.7

Net cash flows from investing activities

–13.0

–14.6

–19.7

–30.9

–17.0

–16.8

–29.6

–38.8

Free cash flow

125.9

59.1

229.5

84.5

56.7

51.0

79.4

43.9

Underlying free cash flow

125.9

59.1

229.5

84.5

56.7

51.0

79.4

43.9

FCR in %

44.4

31.3

43.9

26.4

15.8

17.1

11.2

7.3

ROS in %

53.2

27.4

50.3

20.1

13.1

6.0

14.5

7.0

Merck Millipore

Chemicals

EUR million

Q2
2010

Q2
2009

Jan.–June
2010

Jan.–June
2009

Q2
2010

Q2
2009

Jan.–June
2010

Jan.–June
2009

Sales

–

–

–

–

640.3

482.4

1,220.0

913.4

Royalty and commission income*

–

–

–

–

3.3

4.1

8.2

9.4

Total revenues

–

–

–

–

643.6

486.6

1,228.1

922.8

Gross margin

–

–

–

–

393.5

219.4

746.4

421.5

Marketing and selling expenses*

–

–

–

–

–97.8

–81.8

–185.9

–164.0

Royalty and commission expenses*

–

–

–

–

–3.7

–1.9

–8.9

–4.6

Administration expenses

–

–

–

–

–22.3

–20.5

–42.0

–41.1

Other operating expenses and income

–32.2

–

–32.2

–

–66.1

–9.4

–99.1

–31.0

Research and development

–

–

–

–

–36.5

–34.5

–74.5

–70.7

Operating result

–32.2

–

–32.2

–

166.0

69.7

332.8

106.8

Exceptional items

–

–

–

–

–

–

–

1.2

Earnings before interest and tax (EBIT)

–32.2

–

–32.2

–

166.0

69.7

332.8

108.0

Net operating assets**

–

–

–22.1

–

–

–

2,150.1

1,957.4

Segment liabilities**

–

–

–22.1

–

–

–

–280.3

–230.2

Capital spending on property, plant and equipment

–

–

–

–

28.2

29.2

45.3

63.7

Investments in intangible assets

–

–

–

–

2.3

3.2

3.6

7.6

Depreciation

–

–

–

–

–35.1

–32.0

–70.2

–64.1

Impairment losses

–

–

–

–

–7.4

–0.2

–16.4

–0.2

Net cash flows from operating activities

–8.6

–

–8.6

–

204.0

141.5

349.6

198.1

Net cash flows from investing activities

–

–

–

–

–30.0

–31.3

–49.3

–69.8

Free cash flow

–8.6

–

–8.6

–

174.0

110.1

300.3

128.3

Underlying free cash flow

–8.6

–

–8.6

–

174.0

110.1

300.3

128.3

FCR in %

–

–

–

–

27.0

22.6

24.5

13.9

ROS in %

–

–

–

–

25.8

14.3

27.1

11.6